Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears
- Conditions
- Rotator Cuff TearRotator Cuff Tendinitis
- Interventions
- Device: Adipose Derived Regenerative CellsDrug: Corticosteroid
- Registration Number
- NCT03752827
- Lead Sponsor
- InGeneron, Inc.
- Brief Summary
The purpose of this investigation is to evaluate the safety and superior effectiveness in functional improvement in patients with partial-thickness rotator cuff tears (PTRCTs) after the administration of a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear compared to the administration of a single corticosteroid injection into the associated subacromial space.
- Detailed Description
This is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears comparing a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. 246 subjects assigned to two randomization arms will be enrolled: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to ADRC treatment or active control arms in a 2:1 ratio.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 168
- Males and females 30-75 years of age (inclusive).
- Subjects have a minimum of three (3) months of clinical symptoms consistent with a partial-thickness rotator cuff tear including but not limited to pain, muscle weakness, or limited active range of motion (AROM).
- Subjects have > 70% passive range of motion (PROM) of the index shoulder.
- Subjects have a baseline VAS - Pain score of ≥ 30 mm.
- Subjects have a partial-thickness rotator cuff tear, defined as ≥25% partial-thickness tear of the supraspinatus tendon on a 1.5 Tesla (1.5T) or a 3 Tesla (3T) MRI within the last 3 months, as determined by the Investigator.
- Subjects can give appropriate consent.
-
Age < 30 or > 75.
-
Subject has an insufficient amount of subcutaneous tissue to allow recovery of 100 milliliters (mL) of adipose tissue.
-
Subjects who have received a corticosteroid injection in the index subacromial bursa within the last 3 months.
-
Subjects who have received more than one (1) previous corticosteroid injections or any biologic treatment in the index subacromial bursa within the past 6 months.
-
Subjects with severe arthrosis of the glenohumeral or acromioclavicular joint.
-
Subjects with a full-thickness tear of the rotator cuff.
-
Subjects who have undergone major surgery on the affected shoulder meeting one of the following criteria:
- Performed as treatment for (or required manipulation of) the rotator cuff. Examples include, but are not limited to, subacromial decompression, rotator cuff repair, SLAP repair, arthroplasty and fracture fixation with implants that involve or penetrate the rotator cuff; OR
- Performed using implants that interfere with MR visualization and/or evaluation of the supraspinatus tendon (e.g., biceps tenodesis); OR
- Performed in/on the glenohumeral joint, subacromial space, or acromioclavicular joint within the last 3 years (e.g. soft tissue Bankart repairs performed >3 years ago may still qualify).
NOTE: This exclusion criterion does not apply to minor soft tissue procedures with short recovery periods that do not involve musculoskeletal structures (e.g., lipoma excision).
-
Subjects who were diagnosed with or treated for adhesive capsulitis of the index shoulder within the last 5 years.
-
Subjects with current cervical radiculopathy impacting the index shoulder.
-
Subjects who require the use of index arm for ambulation or mobilization via wheelchair, walker, crutches or cane.
-
Subjects with any contraindication to MRI scan according to MRI guidelines, or who are unwilling to undergo MRI procedures.
-
Subjects whose pain behavior or pain medication usage is, in the opinion of the Investigator, out of proportion to the underlying clinical condition or could interfere with the study- required assessments.
-
Subjects with a history of systemic malignant neoplasms within the last 5 years.
-
Subjects with biopsy-proven, malignant or local neoplasm within the last 6 months or any history of local neoplasm at the site of administration (on the affected arm), excluding basal cell carcinoma.
-
Subject is receiving immunosuppressant therapy or has a known immunologic or severe autoimmune disease that requires chronic systemic immunosuppressive or immunomodulatory therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, rheumatoid arthritis, etc.). [Note: Topical or inhaled corticosteroids are permitted.]
-
Subject is on an active regimen of chemotherapy or radiation- based treatment.
-
Subjects with an allergy to sodium citrate or any "caine" type of local anesthetic.
-
Subject is pregnant or breastfeeding or plans to become pregnant in the next 12 months.
-
Subjects with clinically significant abnormal Lab tests (i.e. basic metabolic panel (BMP) or equivalent (e.g. CHEM-7), complete blood count (CBC), Liver function tests (LFTs), and prothrombin time/international normalized ratio (PT/INR)) as interpreted by the Investigator.
-
Subjects with a history of a bleeding diathesis or coagulopathy
-
Subject is, in the opinion of the Investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. Examples include the inability of the subject to complete patient-reported outcome instruments (PROs) and the inability of the Investigator to perform the injection procedure properly because of anatomic limitations of the subject.
-
Subject is currently participating in another clinical trial that has not yet completed its primary endpoint. (Noninterventional observational studies are not exclusionary.)
-
Subject 1) is a litigant in a civil suit that could affect the subject's ability to complete the study related activities or 2) is a defendant in a criminal case or 3) has an active workman's compensation case in progress.
-
Subject is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent for reasons of incapacity, immaturity, adverse personal. circumstances or lack of autonomy. This may include: individuals with a mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
-
Uncooperative subjects or those with neurological/psychiatric disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Adipose Derived Regenerative Cells Adipose Derived Regenerative Cells Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear Corticosteroid Corticosteroid Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
- Primary Outcome Measures
Name Time Method Improvement or no worsening in supraspinatus strength 24 weeks supraspinatus strength on the MRC Muscle Scale compared to baseline For supraspinatus strength on the MRC Muscle Scale compared to baseline
• For subjects with normal supraspinatus strength (MRC Muscle Scale = 5\] at baseline: no worsening in supraspinatus strength on the MRC Muscle Scale compared to baselineImprovement in Pain: VAS 24 weeks ≥ 14-millimeter (mm) improvement in Visual Analog Scale (VAS)
- Secondary Outcome Measures
Name Time Method Percentage of subjects who demonstrate ≥ 14 mm improvement in VAS 24 weeks Pain score compared to baseline at 24 weeks
Mean improvement in VAS - Pain score 12 and 24 weeks VAS pain score compared to baseline
Mean improvement in WORC score 12 and 24 weeks WORC score compared to baseline
Percentage of subjects who demonstrate a ≥ 1-grade improvement in supraspinatus strength on the MRC Muscle Scale 24 weeks Supraspinatus strength on the MRC Muscle Scale compared to baseline at 24 weeks.
Percentage of subjects who demonstrate improvement or no worsening of supraspinatus strength on the MRC Muscle Scale 24 weeks Supraspinatus strength on the MRC Muscle Scale compared to baseline at 24 weeks
Trial Locations
- Locations (14)
Georgia Institute for Clinical Research
🇺🇸Marietta, Georgia, United States
Andrews Institute for Orthopaedics and Sports Medicine
🇺🇸Gulf Breeze, Florida, United States
Universal Axon Clinical Research
🇺🇸Doral, Florida, United States
Shrock Clinical Research
🇺🇸Fort Lauderdale, Florida, United States
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Sports and Orthopedic Center
🇺🇸Coral Springs, Florida, United States
Lotus Clinical Research, LLC
🇺🇸Pasadena, California, United States
Biosolutions Clinical Research Center
🇺🇸La Mesa, California, United States
Tulane University School of Medicine
🇺🇸New Orleans, Louisiana, United States
Sanford Orthopedic Clinic/Research
🇺🇸Sioux Falls, South Dakota, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Texas Plastic Surgery
🇺🇸San Antonio, Texas, United States
Sanford Medical Center
🇺🇸Fargo, North Dakota, United States
HD Research
🇺🇸Houston, Texas, United States